31/08/2026
Privileged to join an insightful discussion hosted by the Bangladesh Association of Pharmaceutical Industries (BAPI), featuring a guest speaker from the Third World Network (TWN).
The session sparked critical dialogue around international trade agreements, particularly analyzing potential Free Trade Agreement (FTA) dynamics between Bangladesh and the EU.
Key Takeaways from the Presentation:
* IP & Health Exceptions: General WTO health exceptions are notoriously difficult to invoke in disputes (successful only twice in 48 attempts) and typically do not protect Intellectual Property (IP) chapters under proposed EU FTAs.
* Trade Asymmetry & Retaliatory Risk: Bangladesh relies heavily on the EU market—accounting for 48% of its exports—compared to just 0.1% of EU exports going to Bangladesh. Under standard dispute settlement mechanisms, retaliatory tariffs would disproportionately impact Bangladesh's economy and national industries.
* Policy Implications: As Bangladesh navigates international trade frameworks and upcoming LDC graduation, safeguarding public health access, domestic pharmaceutical growth, and constitutional policy space remains essential.
Engaging in discussions like these is crucial for shaping policy-aware strategy in our local landscape.
